Navigation Links
Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

lar novel nuclear Therapeutics 47 export inhibitors (NEIs) in multiple xenograft models 4/18 8:00- 5609 Nuclear Export Experimental 29 14 12:00 Inhibitors and Molecular (NEIs) as novel Therapeutics 47 cancer therapeutics

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.

For additional information on Kosan Biosciences, please visit the company's website at www.kosan
'"/>




Page: 1 2 3

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
9. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
(Date:5/15/2008)...irstCall/ -- Sanofi-aventis,(EURONEXT: SAN and NYS...dmark ATHENA study showed Multaq(R) (dronedarone),... with atrial fibrillation or atrial flutter,decre...r death from any,cause by a statistically signific...endpoint. The ATHENA results will be presented at ...
(Date:5/15/2008)...tch, a publishing and,information services company... finds that investigative sites are required to le.... More than 75% of respondents to a recent,CenterW...n three or more,EDC systems. In addition, a majori...raining had improved., State of the Clinical Tria...
(Date:5/15/2008)...itions Blue Cross Blue Shield of Michigan to ... HealthLeaders-InterStudy, N...ers-InterStudy, the,leading provider of managed ca...y continues to stagnate in Michigan, Blue Cross Bl... all of its competitors to weather the,economic st...
(Date:5/15/2008)... Omega 3 fatty acids bound to,phospholipids deserv...alternative and may have beneficial effect on impu...udy reveals. While several studies have reported,b...nch researchers have,hypothesized that Vectomega(R...control., These research findings have led to the...
Breaking Medicine Technology:Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Veria Announces Acquisition of Massage Envy Ltd 19257 1Veria Announces Acquisition of Massage Envy Ltd 19257 2Veria Announces Acquisition of Massage Envy Ltd 19257 3China Sky One Medical Inc Changes Management Team 5371 1China Sky One Medical Inc Changes Management Team 5371 2China Sky One Medical Inc Changes Management Team 5371 3TOFUTTI Announces First Quarter Results 19251 1TOFUTTI Announces First Quarter Results 19251 2TOFUTTI Announces First Quarter Results 19251 3TOFUTTI Announces First Quarter Results 19251 4ImaRx Postpones Release of First Quarter 2008 Financial Results 5369 1
(Date:5/16/2008)... YONKERS, N.Y., May 16 /PRNewswire-USNewswire/ -...umers Union, the nonprofit publisher of,Consumer R...Bike Commuter,of the Year at CU,s Yonkers headquar... way year round. She bundles up in,the winter and ...om,Larchmont takes her along Quaker Ridge in New R...
(Date:5/16/2008)... NEW YORK, May 16 /PRNewswire/ -- McGraw-Hill Pr...on resources for the scientific and medical,commun...p product,AccessMedicine. Featuring a customizabl...of the clinical and educational tools available on... to locate images, video, and audio., AccessMedic...
(Date:5/16/2008)... STEWARTVILLE, Minn., May 16 /PRNewswire-FirstCa...M ) today announced Dara Lynn Horner,s retirement,...Horner joined the,organization in 1998 and served ... transition, Horner will stay with the Company as ... college days it,s been my aim to take an early re...
(Date:5/16/2008)...Coalition Board Member Educates FDA on Concerns th...ly Impact Patient Safety during Colonoscopy ...., May 16 /PRNewswire/ -- Dr. Stanford Plavin, Boa...Quality Colorectal Cancer,Screening and Care ("Coa...estified on May 7th before the U.S. Food and Drug ...
Breaking Medicine News(10 mins):Health News:Westchester Cycle Club Awards Consumers Union Staffer Karin Weisburgh Commuter of the Year 2Health News:Westchester Cycle Club Awards Consumers Union Staffer Karin Weisburgh Commuter of the Year 3Health News:McGraw-Hill Professional Redesigns AccessMedicine, Highlighting Media and Educational Features 2Health News:Rochester Medical Marketing VP Retires 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Testifies Before FDA Advisory Panel on Fospropofol Labeling: 2
...in day care is that her child will develop a stron...other.// A recent study tht has been published in ...t should put their minds at ease. The study, by ...erlin, the University of Magdeburg-Stendal and Tec...
...bout AIDS/HIV in Bihar, which is posing a major th...icians have decided to launch an awareness drive. ...n the state, politicians, cutting across party lin...the campaign. Uday Narayan Choudhary, the state a...
...al trials published between 2000 and 2005 varied i...ded by for-profit //organizations or by not-for-pr...dy in the May 17 issue of JAMA. Surveys of random... 2000 raised awareness in the medical community th...
...SCID) is a genetic disorder which completely affec...ffered from XSCID in-vivo gene //therapy was succe.... The researchers from the University Of Pennsylva...l Institute of Allergy and Infectious Disease intr...
Other Medicine News:Health News:Mamas Can Set Their Minds to Rest 2Health News:Results of Clinical Trials Vary According to Source of Funding 2Health News:In-Vivo Gene Therapy Technique to Cure XSCID in Basset Pups 2Health News:In-Vivo Gene Therapy Technique to Cure XSCID in Basset Pups 3
...uum Controller V-800 Efficiently controls vacuum...s V-500 on and off as needed to maintain preset va...ane vacuum pump designed to handle most vacuum app...with up to two rotary evaporators Laboratory vac...
...cooled secondary condenser to trap residual solven...acuum pump designed to handle most vacuum applicat...up to two rotary evaporators Laboratory vacuum s...entrators, gel dryers, and filtration apparatuses ...
...0 is a multi-tasking vacuum source and solvent rec...apor trap and a maintenance-free, oil-free vacuum ... wide-mouth glass condensation flask collects all ...posal. The UVS400 provides an ideal vacuum system ...
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)
Medicine Products: